Canada: Pharma In Brief - Federal Court Applies Restrained Approach To Promise Of The Patent And Holds That Methods Of Medical Treatment Are Not Patentable

Case: Bayer Inc v Cobalt Pharmaceuticals Company, 2013 FC 1061

Drug: YAZ® (drospirenone/ethinyl estradiol)

Nature of case: Prohibition proceedings under the Patented Medicines (Notice of Compliance) Regulations

Successful party: Divided

Date of decision: 22 October 2013


This case concerns a proposed generic version of the birth control combination drug YAZ® (drospirenone/ethinyl estradiol). Bayer Inc. and Bayer Pharma Aktiengesellschaft (Bayer) sought an order prohibiting the Minister of Health from issuing a notice of compliance in respect of the proposed generic, developed by Cobalt Pharmaceuticals Company (Cobalt), under section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133.

Bayer relied on Canadian Patents No. 2,382,426 (the '426 Patent) and 2,179,728 (the '728 Patent). Cobalt alleged that the former was invalid for obviousness, inutility, overbreadth, insufficiency, and ambiguity, and that the latter was invalid for obviousness, double-patenting, inutility, and claiming non-patentable subject matter. It further alleged non-infringement in respect of both patents. Justice Hughes agreed with Bayer that Cobalt's allegations regarding the '426 Patent were not justified and issued a prohibition order on that basis. However, Bayer failed to show that Cobalt's non-infringement and non-patentable subject-matter arguments were not justified with respect to the '728 Patent.

This decision is notable for its strong endorsement of a more restrained approach to construction of a patent's promised utility and its analysis of "methods of medical treatment" as a ground of invalidity.

The issues

The '426 Patent concerns oral contraceptive compositions containing drospirenone and ethinyl estradiol, delivered in a form that achieves good oral bioavailability through rapid dissolution, including by micronization of the medicinal ingredient or spraying onto an inert carrier.

The '728 Patent, meanwhile, claims the use of a pharmaceutical composition for oral administration comprising either ethinyl estradiol or 17β-estradiol and a second medicinal ingredient selected from a group of compounds, including drospirenone, for female contraception according to a defined schedule of administration


With respect to the '426 Patent, the issue of non-infringement turned on the construction of a claim to an oral dosage form of drospirenone and ethinyl estradiol defined by its fast rate of dissolution. Having regard to the specification as a whole, Hughes J held that the claim was broad enough to include the Cobalt formulation provided its dissolution time was within the claims of the patent. Because Cobalt provided neither samples of its tablet nor information regarding the tablet's dissolution profile, Hughes J held that its allegation of non-infringement was not justified.

Cobalt also alleged non-infringement of the '728 Patent on the basis that its proposed generic contained more drospirenone than the claimed formulations. In the relevant claims, the quantity of drospirenone is expressed as a range, the upper boundary of which is in each case expressed as the "dose equivalent" of a defined quantity of gestodene (another hormonal contraceptive). Justice Hughes held that neither the patent nor the prior art defined with certainty what the "dose equivalent" would be, and that to the extent such direction could be taken from the prior art, the quantity would most likely be 2 mg. There was no need to come to a settled conclusion because Cobalt's product contained 3 mg of drospirenone and was, in either case, outside the ambit of the claims.


The obviousness analysis was straightforward with respect to both patents in this case. Concerning the '426 Patent, Hughes J agreed with Bayer's expert evidence that the prior art taught away from rapidly-dissolving oral dosage forms of drospirenone without enteric coating. He also held that the prior art cited with respect to the '728 Patent did not disclose drospirenone. Of note, Cobalt unsuccessfully attempted to lead evidence of the "history of the invention" in support of its obviousness allegations regarding the '426 Patent. Justice Hughes found this evidence to be unpersuasive, both because of the piecemeal fashion in which it was assembled and because it was contradicted by Bayer's own evidence from some of the same scientists upon whose work Cobalt relied.


Cobalt's arguments on the utility of the '426 Patent focussed on (1) an allegation that Bayer used a non-micronized form of drospirenone in its testing and (2) a broad construction of the promised utility of the invention. With respect to the first prong, Hughes J agreed with Bayer's uncontradicted evidence that micronized drospirenone was, in fact, tested.

The Court's reasons regarding the "promise" of the '426 Patent are consistent with the more moderate approach described in Sanofi-Aventis v Apotex Inc, 2013 FCA 186. Following that case, Hughes J observed that not all patents contain a promised utility, and that not all statements of advantage rise to the level of a promise. Applying that latter dictum, he concluded that the '426 Patent promised good oral bioavailability resulting from rapid dissolution. This much was demonstrated. By contrast, he held that a statement of the inventors' theory as to the mechanism by which that result is made possible is not a further promise. As such, he agreed that Bayer was not required to demonstrate or soundly predict a correlation between in vitro dissolution and in vivo oral bioavailability, as Cobalt alleged.

Notably, Hughes J did not allow Cobalt to raise inutility arguments that were not present in its notice of allegation through the evidence of one of its experts.

Hughes J also agreed that Cobalt's allegations of inutility with respect to the '728 Patent were not justified, but without any substantial reasons.


Cobalt alleged that the '728 Patent was invalid for double-patenting in light of two other patents owned by Bayer. Curiously, one of these patents was the '426 Patent, the application for which post-dates that of the '728 Patent by over five years. As Hughes J observed, while the earlier-filed '728 Patent might have served as a basis to challenge the validity of the later-filed '426 Patent, the reverse could not be true. The Court also preferred evidence to the effect that the second patent in issue was clearly distinct from the '728 Patent.

Method of medical treatment: Not patentable subject-matter

This is the second recent decision to consider the non-statutory "rule" that methods of medical treatment are not patentable subject-matter. Relying on his own recent analysis in Novartis Pharmaceuticals Canada Inc v Cobalt Pharmaceuticals Company, 2013 FC 985, Hughes J held that four of the five claims in issue were invalid on this ground because, rather than a vendible product, they each claimed a range of components and dosages from which a particular combination must be selected. Only one of the claims in issue, directed at a specific dose of each constituent drug in the combination, survived.

Overbreadth, insufficiency, and ambiguity

Cobalt also argued overbreadth and insufficiency of the '426 Patent. Justice Hughes resolved these issues in favour of Bayer based on his construction of the patent. He also addressed the argument that use of the term "about" preceding measurements rendered the '426 Patent invalid for ambiguity. Justice Hughes held that the USP provided a precise definition for this term with the result that it was not a source of ambiguity.

Link to decision:

Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions